A new report determines the trends fueling drug research and development over the past 10 years—and into the future.
FDA cleared the first medical device to treat attention deficit hyperactivity disorder (ADHD) in kids.
Providing another tool to fight the opioid epidemic, FDA cleared the first generic naloxone hydrochloride nasal spray (Narcan) for use in a community setting.
A Commonwealth Fund study has revealing findings about PBMs’ use of rebates and impact on drug prices.
While pharmacy benefit managers were grilled about insulin prices at Congressional hearings last week, some PBMs, insurers and pharma makers are already lowering insulin costs.
Walgreens is partnering with VillageMD to create primary care clinics in Texas
FDA cleared Dovato (ViiV Healthcare), the first 2-drug regimen to treat HIV-1 in adults with no antiretroviral treatment history.
Metastatic breast cancer drug expands treatment to men.
FDA fast-tracks biosimiliar insulin products to elevate competition.
FDA approved 2 new multiple sclerosis drugs. Here's what you should know about them.